Verona Pharma (Verona Pharma) Long-Term Debt : $48.55 Mil (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Long-Term Debt?

Verona Pharma's Long-Term Debt for the quarter that ended in Mar. 2024 was $48.55 Mil.

Verona Pharma's quarterly Long-Term Debt increased from Sep. 2023 ($19.91 Mil) to Dec. 2023 ($48.37 Mil) and increased from Dec. 2023 ($48.37 Mil) to Mar. 2024 ($48.55 Mil).

Verona Pharma's annual Long-Term Debt increased from Dec. 2021 ($4.87 Mil) to Dec. 2022 ($9.77 Mil) and increased from Dec. 2022 ($9.77 Mil) to Dec. 2023 ($48.37 Mil).

Verona Pharma Long-Term Debt Historical Data

The historical data trend for Verona Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Long-Term Debt Chart

Verona Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

4.64

4.87

9.77

48.37

Verona Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															19.81	19.86	19.91	48.37	48.55

Verona Pharma (GREY:VNAPF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Verona Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verona Pharma (Verona Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

VRNA:USA I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.